NewLink Genetics Corporation (NASDAQ:NLNK) PT Raised to $29.00 at Stifel Nicolaus

NewLink Genetics Corporation (NASDAQ:NLNK) had its price target increased by Stifel Nicolaus from $14.00 to $29.00 in a report issued on Monday, September 11th, MarketBeat.com reports. Stifel Nicolaus currently has a buy rating on the biotechnology company’s stock.

A number of other analysts also recently weighed in on NLNK. Jefferies Group LLC upgraded NewLink Genetics Corporation from a hold rating to a buy rating and lifted their price target for the company from $7.00 to $26.00 in a research note on Friday, September 8th. Cantor Fitzgerald restated a buy rating and issued a $26.00 price target on shares of NewLink Genetics Corporation in a research note on Friday, September 8th. Zacks Investment Research upgraded NewLink Genetics Corporation from a hold rating to a buy rating and set a $12.00 price target on the stock in a research note on Wednesday, June 7th. Robert W. Baird downgraded NewLink Genetics Corporation from an outperform rating to a neutral rating and decreased their price target for the company from $25.00 to $8.00 in a research note on Thursday, June 8th. Finally, ValuEngine downgraded NewLink Genetics Corporation from a sell rating to a strong sell rating in a research report on Friday, June 9th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company’s stock. The company has a consensus rating of Buy and a consensus price target of $24.17.

NewLink Genetics Corporation (NASDAQ:NLNK) opened at 10.81 on Monday. The company’s market capitalization is $318.04 million. The company has a 50 day moving average of $8.77 and a 200 day moving average of $12.66. NewLink Genetics Corporation has a 52 week low of $5.90 and a 52 week high of $25.17.

NewLink Genetics Corporation (NASDAQ:NLNK) last announced its earnings results on Friday, July 28th. The biotechnology company reported ($0.57) earnings per share for the quarter, beating the consensus estimate of ($0.78) by $0.21. NewLink Genetics Corporation had a negative return on equity of 55.03% and a negative net margin of 161.94%. The company had revenue of $10.37 million for the quarter, compared to the consensus estimate of $2.65 million. On average, equities analysts forecast that NewLink Genetics Corporation will post ($2.82) EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This piece was originally published by BBNS and is the sole property of of BBNS. If you are accessing this piece on another publication, it was illegally stolen and republished in violation of U.S. & international copyright & trademark legislation. The correct version of this piece can be viewed at https://baseballnewssource.com/markets/newlink-genetics-corporation-nlnk-price-target-raised-to-29-00/1634207.html.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Northwestern Mutual Wealth Management Co. acquired a new position in shares of NewLink Genetics Corporation in the first quarter worth $145,000. Brandes Investment Partners LP acquired a new position in shares of NewLink Genetics Corporation in the first quarter worth $221,000. UBS Asset Management Americas Inc. acquired a new position in shares of NewLink Genetics Corporation in the first quarter worth $297,000. Teza Capital Management LLC acquired a new position in shares of NewLink Genetics Corporation in the first quarter worth $312,000. Finally, Gotham Asset Management LLC acquired a new position in shares of NewLink Genetics Corporation in the first quarter worth $313,000. 54.78% of the stock is owned by institutional investors.

About NewLink Genetics Corporation

NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications.

Analyst Recommendations for NewLink Genetics Corporation (NASDAQ:NLNK)

Receive News & Ratings for NewLink Genetics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics Corporation and related companies with our FREE daily email newsletter.

 


Latest News

Young Girl Hit by Foul Ball Rushed to Hospital
Young Girl Hit by Foul Ball Rushed to Hospital
New Home Run Record Reached in Major League Baseball
New Home Run Record Reached in Major League Baseball
Will 2017 MLB Season End with No 20-Game Winner?
Will 2017 MLB Season End with No 20-Game Winner?
Cleveland Indians Winning Streak Snapped at 22
Cleveland Indians Winning Streak Snapped at 22
Tigers Player Might Play All Nine Positions During Same Game
Tigers Player Might Play All Nine Positions During Same Game
Fans Kicked Out of Fenway Park After Racist Banner Hung on Green Monster
Fans Kicked Out of Fenway Park After Racist Banner Hung on Green Monster


Leave a Reply

 
© 2006-2017 BBNS.